Regulatory T cells (Tregs): A major immune checkpoint to consider in combinatorial therapeutic HIV-1 vaccines
The field of immunotherapeutics is living an exceptional time as new antibodies that take brakes off T-cells and unleash them on tumours are being approved by the US-Food and Drug Administration (FDA). For the design and development of an HIV-1 therapeutic-vaccine, one would need preferably to shift...
Main Authors: | Audrey Hubert, Nabila Seddiki |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2018-06-01
|
Series: | Human Vaccines & Immunotherapeutics |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/21645515.2018.1434384 |
Similar Items
-
T-Regulatory Cells and Vaccination “Pay Attention and Do Not Neglect Them”: Lessons from HIV and Cancer Vaccine Trials
by: Vedran Brezar, et al.
Published: (2016-09-01) -
The Potential of Immune Modulation in Therapeutic HIV-1 Vaccination
by: Nabila Seddiki, et al.
Published: (2020-07-01) -
Effect of statins as modulators of CD39+ tregs in patients with rheumatoid arthritis who were unsuccessfully treated with methotrexate
by: Mohammed H Abu-Zaid, et al.
Published: (2018-01-01) -
Expression of CD39 Is Correlated With HIV DNA Levels in Naïve Tregs in Chronically Infected ART Naïve Patients
by: Jin-Wen Song, et al.
Published: (2019-10-01) -
Treg and Oligoclonal Expansion of Terminal Effector CD8+ T Cell as Key Players in Multiple Myeloma
by: Douglas E. Joshua, et al.
Published: (2021-02-01)